Newsquawk Logo

Regeneron (REGN) and Telix (TLX) to co-develop and co-commercialise next-gen radiopharmaceutical Therapies in a 50/50 cost and profit-sharing model; Telix to receive USD 40mln upfront and up to USD 2.1bln in milestones

Regeneron and Telix's joint development and commercialization of next-gen radiopharmaceuticals marks a significant strategic partnership in the biotechnology sector.

Newsquawk StaffPublished On the live feed at — 7 more headlines followed before this page went public
Newsquawk headlinesUTC

Leggett & Platt (LEG) to be acquired by Somnigroup International (SGI) in an all-stock transaction valued at approx. USD 2.5bln

French cement maker Lafarge has been found guilty of financing terrorism between 2013 and 2014, by keeping a plant operating in Syria during the war

Regeneron (REGN) and Telix (TLX) to co-develop and co-commercialise next-gen radiopharmaceutical Therapies in a 50/50 cost and profit-sharing model; Telix to receive USD 40mln upfront and up to USD 2.1bln in milestones

[CALENDAR ADDITION] Newly elected Hungarian PM Magyar to hold a post-election press conference at 13:00BST/08:00EDT

German spokesperson says Germany is assuming a US blockade of Iranian ports, not of the Strait of Hormuz

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

The upfront payment coupled with milestone incentives suggests strong expectations for the therapies, which could impact their market valuation and signal confidence in the growth potential for both companies.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.